Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human cytotoxic T lymphocytes
Authors:
- Kenneth C. ParkerKPKenneth C. Parker
- Taku TsukuiTTTaku Tsukui
- C. David PendletonCPC. David Pendleton
- Jay A. BerzofskyJBJay A. Berzofsky
Open Access
- 1 May 1996
- journal article
- research article
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 8 (5) , 641-649
Abstract
P18IIIB is a highly immunogenic peptide from the V3 loop of the HIV-1 gp160 envelope protein that is presented promiscuously by multiple class I MHC molecules. Understanding the molecular basis for promiscuous presentation may have many practical applications. As the highly prevalent HLA-A2.1 class I molecule is known to present P18IIIB for recognition by cytotoxic T lymphocytes (CTL) found in peripheral blood mononuclear cells of HIV+ donors, a P18III-specific CTL line was generated from an HLA-A2+, HIV- donor in order to define the molecular basis for, and ultimately improve upon the binding of, this peptide to HLA-A2.1. The minimal epitope recognized by the line was a decamer,I10, with the sequence RGPGRAFVTI. Interestingly, this decamer is identical to the minimal epitope from P18IIIB seen by murine CTL restricted by H-2Dd. A panel of Ala-substituted peptides was employed in MHC-binding and T cell response studies to identify MHC- and TCR-binding residues. Notably, many of the agretopic and epitopic residues identified were identical to those involved in the corresponding interactions of l10 with the H-2Dd MHC molecule and murine l10-specific CTL. The l10 peptide does not contain the described HLA-A2.1 binding motif. Instead a Pro at P3, a Phe at P7 and an Me at P10 are utilized for MHC binding. Agretopic residue similarities with the hepatitis B nucleocapsid decamer suggest that these residues may comprise an alternative motif of anchors utilized by decamers for binding to HLA-A2.1.Keywords
This publication has 29 references indexed in Scilit:
- Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?Vaccine, 1993
- In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53European Journal of Immunology, 1993
- Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytesEuropean Journal of Immunology, 1993
- Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelopeVaccine, 1993
- Peptide binding to HLA-A2 and HLA-B27 isolated from Escherichia coli. Reconstitution of HLA-A2 and HLA-B27 heavy chain/beta 2-microglobulin complexes requires specific peptides.Journal of Biological Chemistry, 1992
- Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenesNature, 1991
- Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC moleculesNature, 1991
- Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporterNature, 1991
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989
- Genes regulating HLA class I antigen expression in T-B lymphoblast hybridsImmunogenetics, 1985